课题基金 / 基金详情

Alternatives to current Chimeric-Antigen Receptor (CAR)-T cell therapy in acute lymphoblastic leukemia

Alternatives to current Chimeric-Antigen Receptor (CAR)-T cell therapy in acute lymphoblastic leukemia
当前急性淋巴细胞白血病嵌合抗原受体 (CAR)-T 细胞疗法的替代方案
批准号：
368671
负责人：
Haddad Elie
金额：
$50.16万
依托单位：
Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-09-01 至 2022-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=368671&lang=en
关键词：
Acute Lymphoblastic Leukemia Cancer Immunotherapy Cd22 Chimeric Antigen Receptor Engineered Stem Cells Natural Killer Cells Pre-Clinical Mouse Models Specific Promoter Translational Aspect Of Gene Therapy

项目摘要

项目成果

Haddad Elie的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The technology of Chimeric Antigen Receptor (CAR) is a promising new therapeutic tool in Acute Lymphoblastic Leukemia. Usually, patient's own immune cells (T cells) are modified to express the CAR that allows the T cells to both target and kill the patien
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The interplay between Inborn Error of Immunity and blood disorders: unravelling immune defects behind common haematological diseases
Empowering innovative hematopoietic stem cells (HSC)-based cancer immunotherapy through the creation of synthetic specific promoters
New Modalities of Chimeric Antigen Receptor (CAR) Therapies in Pediatric Rhabdomyosarcoma
Platform of synthetic specific promoters for immunotherapies and regenerative medicine
海外基金